Biotech entity
funding is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Anthony Fauci, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention DIA, all published on July 31, 2026.
Last mentioned: Jul 31, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
funding is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Anthony Fauci, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention DIA, all published on July 31, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering DIA. Shared-story counts are live from our verified record — not editorial picks.
Senators react
Sens. Rand Paul and Ron Johnson publicly call for legal challenges to the pardon, state-level prosecution, and full investigations into Fauci’s actions.
Gabbard releases intelligence files
Outgoing DNI Tulsi Gabbard declassifies and releases trove of documents alleging Fauci’s deception and funding of Wuhan gain-of-function research.
Preemptive pardon granted
President Biden issues a preemptive pardon to Fauci before leaving office, covering potential federal crimes related to the pandemic.
Fauci testifies to Congress
Fauci testifies that he had no contact with intelligence agencies regarding viral research, a claim now contradicted by Gabbard's files.
Outgoing DNI Tulsi Gabbard’s intelligence release alleges Dr. Anthony Fauci directed millions in taxpayer dollars to fund dangerous bat coronavirus research at the Wuhan lab, threatening public trust and likely triggering a regulatory crackdown on gain-of-function studies across the biotech sector.
Source: fox11online.com · ktul.com
DIA is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
